Here's My Risk and Reward Parameters for Vir Biotechnology

Let's look over the charts and indicators.

Karuna Therapeutics Is Doing Important Research but Its Charts Are Weak

The technical signals of the clinical-stage biotech company don't inspire confidence at this juncture.

Thrill Seekers Might Like 2 Downtrodden Stocks Insiders Are Buying

TherapeuticsMD and Spark Networks are beaten-down names with recent buying interest from insiders in common.

Market Participants Are Battling Omicron Pessimism

There are a number of issues to consider from a trading standpoint as we start the week.

Fingers Crossed for a Small-Cap Revenge Rally in 2022

The lingering effects of the pandemic have been hard on smaller biotech and healthcare stocks, but the worm could turn next year.

How to Play AstraZeneca as Earnings Approach

Let's see how the charts are shaping up ahead of the numbers Friday.

GE Plans to Split Into 3: Here's MY Plan

Since GE CEO Larry Culp took the reins three years ago his plan has been nothing if not aggressive.

Options Play of the Week: Dipping Into Dynavax

Knee-jerk reactions to earnings results can create attractive opportunities.

Will Humana's Earnings Numbers Generate an Upside Breakout?

Let's take a look at the charts of this healthcare provider ahead of Wednesday's report.